NovaBay Pharmaceuticals Inc’s wound cleanser NeutroPhase achieved better results in lab tests, killing bacteria in less than a minute
Feb 18, 2014 (Menafn – M2 EQUITYBITES via COMTEX) –Biopharmaceutical company NovaBay Pharmaceuticals Inc (nyse mkt:NBY) stated on Monday that its wound cleanser, NeutroPhase, has achieved better results in lab tests than 18 other commercial products.
The company said this new study was published in the journal Advances in Skin & Wound Care. The study found that, unlike any of the other products, NeutroPhase was able to kill bacteria in less than a minute. NeutroPhase, in contrast with the other commercially available wound cleansers involved in the study, has the fastest bactericidal activity at concentrations that are safe for human cells.
In the study, researchers took 19 commercial wound cleansers and diluted each one until it was no longer harmful to mammalian cells (in this case, mouse skin cells). Then, the researchers tested each cleanser’s anti-microbial activity. At these dilution levels, only NeutroPhase was able to kill bacteria in less than one minute, said the company.
According to the company, NeutroPhase is pure hypochlorous acid (0.01% concentration) in saline that has received FDA 510(k) clearance as a skin and wound cleanser. Hypochlorous acid is a natural substance produced by white blood cells as a first defense against microbial invaders. NeutroPhase contains a higher concentration of pure hypochlorous acid than other wound cleansers which contain harmful impurities such as sodium hypochlorite (bleach), such as Dakin’s solution.